B
Brent A. Blumenstein
Researcher at Fred Hutchinson Cancer Research Center
Publications - 54
Citations - 7944
Brent A. Blumenstein is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Prostate cancer & Chemotherapy. The author has an hindex of 25, co-authored 51 publications receiving 7615 citations. Previous affiliations of Brent A. Blumenstein include Johns Hopkins University School of Medicine & University of Oklahoma Health Sciences Center.
Papers
More filters
Journal ArticleDOI
Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.
Robert C. Flanigan,Sydney E. Salmon,Brent A. Blumenstein,Scott I. Bearman,Vivek Roy,Patrick C. McGrath,John R. Caton,Nikhil C. Munshi,E. David Crawford +8 more
TL;DR: Nephrectomy followed by interferon therapy results in longer survival among patients with metastatic renal-cell cancer than does interferons therapy alone.
Journal ArticleDOI
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
E. D. Crawford,Mario A. Eisenberger,David G. McLeod,J T Spaulding,Ralph C. Benson,F A Dorr,Brent A. Blumenstein,M A Davis,P J Goodman +8 more
TL;DR: Treatment with le uprolide and flutamide is superior to treatment with leuprolide alone in patients with advanced prostate cancer, and Symptomatic improvement was greatest during the first 12 weeks of the combined androgen blockade.
Journal ArticleDOI
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer
Mario A. Eisenberger,Brent A. Blumenstein,E. David Crawford,Gary J. Miller,David G. McLeod,Patrick J. Loehrer,George Wilding,Kathy Sears,Daniel J. Culkin,Ian M. Thompson,Anton J. Bueschen,Bruce A. Lowe +11 more
TL;DR: The addition of flutamide to bilateral orchiectomy does not result in a clinically meaningful improvement in survival among patients with metastatic prostate cancer.
Journal ArticleDOI
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials
Otilia Dalesio,H. van Tinteren,Mike Clarke,Richard Peto,Fritz H. Schröder,I Dechering,V Evans,Jon Godwin,Brent A. Blumenstein,E. D. Crawford,Louis Denis,R Hall,Catherine Hill,P Iversen,W U Shipley,M. Soloway,Richard Sylvester,Collaborat Pct. +17 more
TL;DR: In advanced prostate cancer, addition of an antiandrogen to AS improved the 5-year survival by about 2% or 3% (depending on whether the analysis includes or excludes the cyproterone acetate trials), but the range of uncertainty as to the true size of this benefit runs from about 0% to about 5%.
Journal ArticleDOI
A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder.
Donald L. Lamm,Brent A. Blumenstein,E. D. Crawford,Montie Je,Scardino P,Grossman Hb,Thomas H. Stanisic,Joseph A. Smith,Sullivan J,Michael F. Sarosdy +9 more
TL;DR: As compared with intravesical doxorubicin, immunotherapy with BCG provides improved protection against the recurrence of superficial bladder cancer.